GRIFOLS ADR 1/2/EO-50 (F:G0F) — Market Cap & Net Worth
Market Cap & Net Worth: GRIFOLS ADR 1/2/EO-50 (G0F)
GRIFOLS ADR 1/2/EO-50 (F:G0F) has a market capitalization of $4.21 Billion (€3.60 Billion) as of May 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #4025 globally and #713 in its home market, demonstrating a -1.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GRIFOLS ADR 1/2/EO-50's stock price €4.26 by its total outstanding shares 844570736 (844.57 Million).
GRIFOLS ADR 1/2/EO-50 Market Cap History: 2022 to 2026
GRIFOLS ADR 1/2/EO-50's market capitalization history from 2022 to 2026. Data shows change from $5.13 Billion to $4.03 Billion (-13.39% CAGR).
GRIFOLS ADR 1/2/EO-50 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GRIFOLS ADR 1/2/EO-50's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of G0F by Market Capitalization
Companies near GRIFOLS ADR 1/2/EO-50 in the global market cap rankings as of May 4, 2026.
Key companies related to GRIFOLS ADR 1/2/EO-50 by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $862.20 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #23 globally with a market cap of $547.37 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #37 globally with a market cap of $365.30 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $862.20 Billion | $963.33 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #23 | Johnson & Johnson | NYSE:JNJ | $547.37 Billion | $227.19 |
| #37 | AbbVie Inc | NYSE:ABBV | $365.30 Billion | $206.60 |
GRIFOLS ADR 1/2/EO-50 Historical Marketcap From 2022 to 2026
Between 2022 and today, GRIFOLS ADR 1/2/EO-50's market cap moved from $5.13 Billion to $ 4.03 Billion, with a yearly change of -13.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €4.03 Billion | -21.54% |
| 2025 | €5.13 Billion | +21.50% |
| 2024 | €4.23 Billion | -42.16% |
| 2023 | €7.31 Billion | +42.31% |
| 2022 | €5.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of GRIFOLS ADR 1/2/EO-50 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.21 Billion USD |
| MoneyControl | $4.21 Billion USD |
| MarketWatch | $4.21 Billion USD |
| marketcap.company | $4.21 Billion USD |
| Reuters | $4.21 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GRIFOLS ADR 1/2/EO-50
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more